Prior Radiotherapy Improves Progression-free Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Tremelimumab–Durvalumab
Anticancer Research · 2025
DOI: 10.21873/anticanres.17903 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2025. Verfasst von Akifumi Kuwano und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan; akuwnaoh1@aih-net.com. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan; akuwnaoh1@aih-net.com.
- Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan.
- Department of Gastroenterology, Ichinomiyanishi Hospital, Ichinomiya, Japan.
- Department of Diagnostic Pathology, Aso Iizuka Hospital, Iizuka, Japan.
- Department of Radiation Oncology, Aso Iizuka Hospital, Iizuka, Japan.
Zitieren
APA
Kuwano, A., Tanaka, K., Hamamoto, T., Kurosaka, K., Suzuki, H., Yada, M., Ohishi, Y., Sasaki, T., & Motomura, K. (2025). Prior Radiotherapy Improves Progression-free Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Tremelimumab–Durvalumab. Anticancer Research. https://doi.org/10.21873/anticanres.17903
Vancouver
Kuwano A, Tanaka K, Hamamoto T, Kurosaka K, Suzuki H, Yada M, et al. Prior Radiotherapy Improves Progression-free Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Tremelimumab–Durvalumab. Anticancer Research. 2025. doi:10.21873/anticanres.17903
BibTeX
@article{Kuwano2025,
author = {Kuwano, Akifumi and Tanaka, Kosuke and Hamamoto, Taikan and Kurosaka, Kazuki and Suzuki, Hideo and Yada, Masayoshi and Ohishi, Yoshihiro and Sasaki, Tomonari and Motomura, Kenta},
title = {Prior Radiotherapy Improves Progression-free Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Tremelimumab–Durvalumab},
journal = {Anticancer Research},
year = {2025},
doi = {10.21873/anticanres.17903}
}
EUVIMED